Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy?

Background and purposeDiabetic distal sensorimotor polyneuropathy (DSPN) is a frequent, disabling complication of diabetes mellitus. There is increasing evidence that sphingolipids play a role in insulin resistance and type 2 diabetes (T2DM). Whether neurotoxic 1-deoxy-sphingolipids are elevated in DSPN patients' plasma and whether levels correlate to the DSPN stage were examined. MethodsThe plasma profile of 12 sphingoid bases in patients with DSPN and T2DM(n=39) were cross-sectionally compared to other nerve disorders including chronic inflammatory demyelinating polyneuropathy (CIDP) (n=13), transthyretin-related familial amyloid polyneuropathy (FAP) (n=10), amyotrophic lateral sclerosis (ALS) (n=13) and small fibre neuropathy (n=12) by liquid chromatography mass spectrometry. Correlations to the DSPN stage were additionally performed. Furthermore, the sphingoid base distribution in sural nerve specimens was measured in patients with DSPN (n=6) compared to CIDP (n=3). ResultsA significantly increased amount of 1-deoxy-sphingolipids [1-deoxy-sphinganine (0.110.06mol/l), 1-deoxy-sphingosine (0.24 +/- 0.16mol/l)] in patients with DSPN was observed compared to age-matched healthy controls (0.06 +/- 0.03mol/l; 0.12 +/- 0.05mol/l) and to the other groups. (Para)clinical parameters including sensory loss, neuropathic pain, weakness, vibration perception, nerve conduction velocity, sensory nerve action potentials (sural nerve) and duration of T2DM did not correlate with plasma 1-deoxy-sphingolipid levels, neither did the clinical stage according to the Dyck classification for DSPN. Sphingolipid levels in sural nerve biopsies showed no differences between DSPN and CIDP. Contrarily, patients with a small fibre neuropathy had decreased C-20-sphingosine plasma levels. Conclusion1-deoxy-sphingolipid plasma levels are significantly elevated in DSPN. They are already detectable in early disease stages but do not correlate with the clinical course. Further knowledge on 1-deoxy-sphingolipids might lead to a better pathophysiological understanding and future treatment options in DSPN.